SMid Biotech Analyst Rama provides a quick recap of Revuforj Physician Survey results on a conference call to be held on March 20 at 10 am hosted by JPMorgan. Webcast Link
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax price target raised to $41 from $39 at JPMorgan
- Strong Buy Rating for Syndax Pharmaceuticals Driven by Revuforj’s Market Potential and Revenue Growth
- Positive Outlook on Syndax Pharmaceuticals: Strong Market Presence and Strategic Growth Initiatives
- Syndax price target raised to $39 from $35 at JPMorgan
- Syndax price target lowered to $42 from $45 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue